Protocol Ledger

NCT04768972 · Phase III · ACTIVE NOT RECRUITING

FUSION: A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ION363 in Amyotrophic Lateral Sclerosis Participants With Fused in Sarcoma Mutations (FUS-ALS)

Interventional Phase III clinical trial protocol NCT04768972 sponsored by Ionis Pharmaceuticals in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-06-14 Enrollment: 89 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04768972
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)89 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04768972
Protocol FieldVerified Registry Value
NCT IdentifierNCT04768972
Consolidated Lead SponsorIonis Pharmaceuticals
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment89 participants (ACTUAL)
Registered Start Date2021-06-14
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI